Our clinical trial expertise. Your drug discovery pipeline.
At Aquila, we support you in successfully bringing your novel immunotherapy through clinical trials to market.
We offer a variety of clinical research services, including validated biomarker assays to evaluate the immune response to your drug candidate within the tumour and the TME, utilising readout technologies such as MSD’s MESO QuickPlex SQ120 for rapid, highly sensitive results.
As a specialist company that combines academic expertise with industrial standards, we use automated platforms to predict efficacy and safety of novel immuno-therapeutics.
In addition, we stratify patient response to your therapy with multiplex analysis of proteins and their spatial distribution within the tumour and/or TME. Our multiplex staining panels can be customised to meet a specific biomarker strategy during pre-clinical stages and beyond.
Please get in touch to learn more about how we can support your clinical trial.